(EVGN) Evogene Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
Actionable Strategy Starts Here
This Evogene Ltd. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format and shows how these elements support positioning and sales. The page includes a real preview/sample of the analysis so you can assess style and content before buying; purchase the full version to get the complete ready-to-use report.
Product
Computational Predictive Biology platform
Evogene Ltd.’s core product is its Computational Predictive Biology platform, which uses big data and AI to spot promising life-science leads faster than wet-lab screening alone. It supports R&D across multiple sectors, so the product is also the engine behind the company’s pipeline and partner work. In the 4P mix, it is the main value driver because it turns biological data into actionable discovery decisions.
Agricultural seed traits
Evogene Ltd.’s Agricultural seed traits product line focuses on improving crop performance and yield across 5 major crops: corn, soybean, wheat, rice, and cotton. These traits are built to help growers raise productivity and get more from each planted hectare. In 2025, this matters most in crops that account for hundreds of millions of hectares worldwide.
Agricultural chemicals and biologicals
Evogene’s agricultural chemicals and biologicals aim to lift plant health and crop output, a market pulled by the fact that FAO says pests and diseases still cut 20% to 40% of global crop yields each year. The product fits Evogene’s data-driven model by using predictive tools to screen and design more targeted agri-solutions. That helps farmers seek higher yield with less waste and better field performance.
Human microbiome therapeutics
Evogene Ltd.'s Human Health division pursues microbiome-based therapeutics for immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. That keeps the pipeline focused on high-unmet-need markets where better drugs can win fast if clinical data land well. The core product angle is discovery, not retail demand, so product value depends on target biology, success rates, and partner interest.
- Targets unmet medical needs.
- Focuses on microbiome-based treatments.
- Plans for oncology and GI use.
- Also addresses drug-resistant infections.
Medical cannabis offerings
Through Canonic Ltd., Evogene participates in medical cannabis product development, adding a consumer-health line to its platform businesses. Its work with Cannbit Ltd. supports breeding and product development, tying Evogene’s gene-tech stack to a regulated wellness market. This segment is still niche, but it broadens Evogene’s product base beyond software-like platforms.
- Canonic drives medical cannabis exposure.
- Cannbit supports development work.
- Adds a health-focused product line.
Evogene’s AI Platform Powers Multiple Growth Markets
Evogene Ltd.’s Product mix centers on its AI-driven Computational Predictive Biology platform, which turns large biological datasets into faster discovery decisions. In 2025, that platform feeds crop traits, ag-biologicals, human health, and medical cannabis work, so one core engine supports several end markets. Its value is in shortening R&D time and improving hit rates.
| Area | Focus |
|---|---|
| Core | AI biology platform |
| Agriculture | 5 major crops |
| Health | Microbiome therapies |
| Cannabis | Canonic line |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Evogene Ltd.’s product, price, place, and promotion strategy, grounded in real market positioning.
Editable Excel File
Condenses Evogene Ltd.’s 4Ps into a quick, structured snapshot that saves time and simplifies strategic marketing review.
Reference Sources
Cites industry reports, peer-reviewed studies, and company filings to speed due diligence and let investors verify Evogene’s market, pricing, and unit-economics claims.
Place
United States operations
Evogene uses the United States as a core base for R&D, partner work, and commercial talks in life sciences. The market matters because it is the largest life sciences and agtech arena, so it gives Evogene access to fast-moving agriculture and health customers. U.S. operations help the Company test products, build alliances, and move from research to revenue faster.
Israel headquarters
Evogene Ltd.’s headquarters is in Rehovot, Israel, and it serves as the company’s main operating base for technology and research. This location anchors its computational biology work, which supports its platform-driven product development. With one central hub in Israel, Evogene keeps its core science, data, and research teams closely linked.
Brazil market presence
Evogene’s Brazil presence matters because Brazil is one of the world’s biggest crop markets, led by soybeans, corn, and sugarcane. That local footprint gives the Company access to large-scale farming use cases where trial sizes, grower density, and adoption potential are much larger than in many smaller markets. For agriculture partners, Brazil is a direct route to high-volume field validation and commercialization.
Global partner network
Evogene Ltd. uses a global partner network to bring products and platforms to market through BASF SE, Corteva, and Bayer, so reach goes far beyond direct sales. With 3 named global partners, the model gives Evogene wider market access without carrying a full sales force in every region.
- BASF SE, Corteva, Bayer
- 3 major partners
- Broader global reach
Subsidiary-led distribution
Evogene Ltd. uses subsidiary-led distribution through Canonic Ltd. to target niche markets like medical cannabis. Canonic’s tie-up with Cannbit Ltd. helps move products through regulated Israeli channels, so the place strategy stays local, segmented, and region-specific. Evogene reported $7.4 million revenue in 2024.
- Canonic expands market reach.
- Cannbit supports medical cannabis access.
- Distribution fits local regulation.
Evogene’s Hub-and-Partner Model Scales Global Reach
Evogene’s Place strategy is hub-and-partner led: Rehovot anchors R&D, the U.S. drives research and commercial talks, and Brazil supports large-scale field validation. Three major partners, BASF SE, Corteva, and Bayer, extend reach without a heavy direct-sales network. Canonic adds niche distribution in regulated cannabis markets. Evogene reported $7.4 million revenue in 2024.
| Channel | Role |
|---|---|
| Israel | Core R&D hub |
| United States | Partner and commercial base |
| Brazil | Field-scale market access |
| 3 partners | BASF SE, Corteva, Bayer |
Preview the Actual Deliverable
Evogene Ltd. Reference Sources
The preview shown here is the actual Evogene Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.
You're viewing the exact final version of the analysis—comprehensive, high-quality, and identical to the file included with your order.
Promotion
BASF, Corteva, Bayer partnerships
Three alliances with BASF SE, Corteva, and Bayer act as strong promotion proof for Evogene Ltd.'s agtech platform. In a sector where a single large partner can de-risk adoption, these ties signal that multiple global leaders have tested the technology. That credibility can speed talks with other customers and collaborators.
Scientific technology positioning
Evogene positions itself as a computational biology and AI-driven discovery company, with its CPB platform at the center of that story. That message makes Company Name look like a science-led innovator, not a traditional product seller. This is reinforced by its 2025 filing focus on platform-based discovery, where value comes from R&D output and IP, not volume sales.
Division-focused communications
Evogene Ltd. communicates through three clear divisions: Agriculture, Human Health, and Industrial Applications. That division-based messaging helps it speak to distinct stakeholder groups with the right data, from crop performance to biotech and bio-based products. The structure also fits its 2025 reporting around 3 core markets, each with its own development path and value story.
Joint development visibility
Joint development visibility helps Evogene Ltd. turn partner deals into proof of pipeline progress and commercial intent. A collaboration like Canonic with Cannbit adds outside validation and more media reach, which is useful in niche medical cannabis markets. It also makes the science easier to track for investors and potential buyers.
Builds trust through partner validation
Shows pipeline progress in public
Expands reach in medical cannabis
Global life-science presence
Evogene’s footprint in the United States, Israel, Brazil, and other markets gives it a clear global-life-science story, which matters in partner talks and licensing. In 2025, that multi-region setup helped the Company present one platform with uses across agtech and other biotech areas, not a single-country niche.
- US, Israel, Brazil reach
- Global platform positioning
- Attracts partners and licensees
- Supports investor visibility
Partner-Backed Growth Fuels Evogene’s Global Story
Promotion for Evogene Ltd. leans on partner proof, not mass ads: BASF SE, Corteva, and Bayer validate the platform, while 3 core business lines keep the message focused. In 2025, this science-led framing helped back a global story across the US, Israel, and Brazil.
| Metric | Value |
|---|---|
| Major alliances | 3 |
| Core segments | 3 |
| Key regions | 3+ |
Price
B2B licensing model
Evogene Ltd. prices through B2B licensing and collaboration deals, so fees are negotiated case by case instead of set retail prices. Value comes from access to its discovery platform and R&D engine, which was still the core of its latest reported business model in 2025 filings. That makes pricing tied to milestones, usage rights, and partner scope, not consumer demand.
Milestone-based economics
Evogene Ltd.'s milestone-based pricing fits life-science deal norms, where payments usually track research, development, or commercialization steps. That means partners pay less upfront and Evogene gets paid when technical gates are hit, so revenue is tied to progress, not just contracts signed. It rewards success, but cash flow can be uneven between milestones.
Royalty-linked value capture
Evogene Ltd. can capture value on developed products through royalties or downstream participation, so pricing rises only if a partner program wins in market. In platform-led innovation, this is a common model: partner deals often shift upfront risk away from Company Name and tie upside to launch success, with royalty rates in many life-science deals landing in the low-single to low-double digits. That keeps pricing aligned with real commercial demand.
Premium innovation pricing
Evogene Ltd.'s AI and data-driven discovery platform supports premium pricing because customers pay for speed, higher precision, and less discovery risk. The value is not the tool itself, but the time and R&D cost it can save versus trial-and-error workflows.
That makes the price premium easier to defend when buyers are trying to cut long R&D cycles and avoid failed programs. In 2025, this kind of platform-led model stayed tied to measurable productivity gains, not just software features.
- Speed up discovery decisions
- Lower failed-R&D risk
- Price on saved time
Segment-specific negotiated terms
Evogene Ltd. prices by segment, not one list price. Agriculture, human health, industrial applications, and medical cannabis each face different R&D timelines, regulatory costs, and upside, so deals are negotiated case by case.
This is the only practical model: crop programs can span years, while human health and medical cannabis need heavier compliance and proof steps, which pushes pricing toward milestone and license terms instead of a fixed fee.
- Segment needs drive price.
- Negotiated terms fit long development cycles.
- Regulation changes the cost base.
- Value depends on market potential.
Evogene’s pricing is progress-based, with upside tied to royalties
Evogene Ltd. prices its platform through negotiated B2B licenses, not list prices, so fees depend on scope, milestones, and partner rights. In 2025 filings, this model stayed tied to R&D value, with upside often shifting to royalties or downstream participation. That keeps price linked to progress, not volume.
| 2025 pricing driver | What it means |
|---|---|
| Licenses | Case-by-case fees |
| Milestones | Paid on progress |
| Royalties | Upside on launch |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.